Antistaphylococcal activity of the novel cephalosporin CB-181963 (CAB-175)
Open Access
- 1 April 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 55 (4), 579-582
- https://doi.org/10.1093/jac/dki003
Abstract
Objectives: We examined the antistaphylococcal activity of the novel cephalosporin CB-181963 (formerly known as CAB-175), with emphasis on its microbiological activity and penicillin-binding protein specificities. Methods: Using established procedures, we examined the activity of CB-181963 against methicillin-susceptible (MSSA) and methicillin-resistant (MRSA) strains of Staphylococcus aureus in both planktonic and biofilm culture. We also determined whether CB-181963 exhibited a post-antibiotic effect (PAE). A radioactive competition assay with 3H-labelled benzylpenicillin was used to determine penicillin-binding protein (PBP) affinities of CB-181963, including binding to PBP2a from MRSA. The potential for emergence of CB-181963-resistant mutants in MSSA and MRSA strains was examined using plating procedures. Results: CB-181963 showed excellent activity against MRSA strains resistant to other cephalosporins in both planktonic and biofilm cultures. However, in common with other cephalosporins it was unable to eradicate biofilms. CB-181963 had a short PAE compared with other β-lactam antibiotics. CB-181963 retained activity against a strain expressing type A β-lactamase and demonstrated affinity for PBP2a of MRSA. Mutants resistant to CB-181963 were not recovered in either MSSA or MRSA. Conclusions: CB-181963 is a potent antistaphylococcal agent with better activity against MRSA than other cephalosporins. The anti-MRSA activity is correlated with elevated binding to PBP2a. CB-181963 may have a role in the treatment of staphylococcal infections, including those caused by MRSA and in the prophylaxis of biofilm-associated MSSA and MRSA infections. However, because of its short PAE, CB-181963 may have to be administered more frequently than other β-lactam antibiotics, or given via prolonged infusion.Keywords
This publication has 7 references indexed in Scilit:
- In Vitro Activities of a Novel Cephalosporin, CB-181963 (CAB-175), against Methicillin-Susceptible or -Resistant Staphylococcus aureus and Glycopeptide-Intermediate Susceptible StaphylococciAntimicrobial Agents and Chemotherapy, 2004
- In Vitro Activity of S-3578, a New Broad-Spectrum Cephalosporin Active against Methicillin-Resistant StaphylococciAntimicrobial Agents and Chemotherapy, 2003
- RWJ-54428 (MC-02,479), a New Cephalosporin with High Affinity for Penicillin-Binding Proteins, Including PBP 2a, and Stability to Staphylococcal Beta-LactamasesAntimicrobial Agents and Chemotherapy, 2003
- Mutation frequencies for resistance to fusidic acid and rifampicin in Staphylococcus aureusJournal of Antimicrobial Chemotherapy, 2001
- Cloning and Characterization of a Gene, pbpF , Encoding a New Penicillin-Binding Protein, PBP2B, in Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 1999
- Penicillin-Binding Protein 2a from Methicillin-Resistant Staphylococcus aureus: Kinetic Characterization of Its Interactions with β-Lactams Using Electrospray Mass SpectrometryBiochemistry, 1999
- Persistent Effect of Antibiotics on Staphylococcus aureus after Exposure for Limited Periods of TimeThe Journal of Infectious Diseases, 1977